Brukinsa®
(Zanubrutinib)
An antineoplastic medicinal product, a selective small-molecule Bruton’s tyrosine kinase (BTK) inhibitor.1
Indications
- Mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.
- Monotherapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in adult patients.
- Monotherapy for Waldenström’s macroglobulinemia (WM) in adult patients who have received at least one prior chemotherapy regimen, or as first-line therapy in patients for whom standard chemoimmunotherapy regimens are unsuitable.
- Marginal zone lymphoma (MZL) in adult patients who have received at least one prior anti-CD20–based therapy.
Dosage form
Capsules, 80,0 mg
Age restrictions
Adults aged 18 years and older
Dosage regimen
160 mg (2 capsules) twice daily or 320 mg (4 capsules) once daily. Treatment is recommended to continue until disease progression or unacceptable toxicity.
Manufacturing and Registration
Name and legal address of the marketing authorization holder:
BeiGene Pharmaceuticals GmbH, Eschengraben 27, 4051 Basel, Switzerland.
Name and address of the organization authorized by the marketing authorization holder to receive consumer complaints regarding the medicinal product:
Nanolek LLC, Russia, 123112, Moscow, Presnensky Municipal District, Testovskaya St., 10, premises 1/16. Email: info@nanolek.ru.
Official Documents
-
1.
GRLS. Instructions for medical use of the medicinal product «Brukinsa» (zanubrutinib).
Accessed: 17.07.2025.